Sleep chart of biological aging clocks across organs and omics

The MULTI study[#], Cliodhna Kate O'Toole[1], Zhiyuan Song[1], Filippos Anagnostakis[1], Zhijian Yang[2], Ye Ella Tian[3], Michael R. Duggan[4], Chunrui Zou[5], Yue Leng[6], Yi Cai[7], Wenjia Bai[8], Cynthia H.Y. Fu[9,10,11], Michael S. Rafii[12], Paul Aisen[12], Gao Wang[13], Philip L. De Jager[14], Jian Zeng[15], Hamilton Se-Hwee Oh[16,17,18,19], Xia Zhou[20], Keenan A. Walker[4], Daniel W. Belsky[21], Andrew Zalesky[3], Eleanor M. Simonsick[22], Susan M. Resnick[4], Luigi Ferrucci[23], Christos Davatzikos[24], Junhao Wen[1,5,25,26,27,28,29,*]

[1]Laboratory of AI and Biomedical Science (LABS), Columbia University, New York, NY, USA
[2]GE Healthcare, Bellevue, WA, USA
[3]Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
[4]Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
[5]Department of Radiology, Columbia University, New York, NY, USA
[6]Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA
[7]Department of Otolaryngology–Head and Neck Surgery, Columbia University, New York, NY, USA
[8]Department of Brain Sciences and Department of Computing, Imperial College London, London, UK
[9]School of Psychology, University of East London, London, UK
[10]Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
[11]National Institute for Health and Care Research (NIHR), Maudsley Biomedical Research Centre (BRC), London, UK
[12]Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA 92121, USA
[13]Department of Neurology, Columbia University, New York, NY, USA
[14]Center for Translational & Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, NY, USA
[15]Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia
[16]Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[17]Brain and Body Research Center of the Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[18]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[19]Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[20]Department of Computer Science, Columbia University, New York, NY, USA
[21]Robert N Butler Columbia Aging Center and Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, USA
[22]Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, Baltimore, MD, USA.
[23]National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
[24]Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI^{2}D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[25]Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID), Department of Radiology, Columbia University, New York, NY, USA
[26]Department of Biomedical Engineering, Columbia University, New York, NY, USA
[27]Zuckerman Institute, Columbia University, New York, NY, USA
[28]New York Genome Center (NYGC), New York, NY, USA
[29]Data Science Institute (DSI), Columbia University, New York, NY, USA

[*]Corresponding author:
Junhao Wen, junhao.wen89@gmail.com; 622 W 168th St, New York, NY 10032
[#]Study representative: Dr. Junhao Wen

Abstract

Optimal sleep plays a vital role in promoting healthy aging and enhancing longevity. This study proposes a Sleep Chart to assess the relationship between sleep duration and 23 biological aging clocks across 17 organ systems or tissues and 3 omics data types (imaging, proteomics, and metabolomics). First, a systemic, U-shaped pattern shows that both short (<6 hours) and long (>8 hours) sleep duration are linked to elevated biological age gaps (BAGs) across 9 brain and body systems and 3 omics types, with optimal sleep time varying by organ and sex ([6.4-7.8] hours). Furthermore, short and long sleep duration, compared to a normal sleep duration ([6-8] hours), are consistently linked to increased risk of systemic diseases beyond the brain and all-cause mortality, with evidence from genetic correlations and time to incident disease predictions, such as migraine, depression, and diabetes. Finally, short and long sleep duration are associated with late-life depression via distinct pathways: long sleep may contribute indirectly through biological aging processes, while short sleep shows a more direct link. Although our Mendelian randomization does not show strong causal effects from disease to sleep disturbances, it does not fully rule out the possibility that sleep disturbances may, in part, reflect underlying disease burden. Our findings suggest that the U-shaped relationship is likely driven by modifiable sleep disturbances rather than genetic predisposition, highlighting the potential of sleep optimization to support healthy aging, lower disease risk, and extend longevity. An interactive web portal is available to explore the Sleep Chart at: https://labs-laboratory.com/sleepchart.

Main

Sleep is a fundamental biological process essential for physical restoration, cognitive functioning, and overall health[1]. Increasing evidence underscores its association with aging[2], disease susceptibility[3], and longevity[4]. Both insufficient and excessive sleep duration have been linked to a wide range of adverse health outcomes, including cardiometabolic disease[5], cognitive decline[6], and psychiatric disorders[7], such as late-life depression (LLD[8]). Importantly, sleep is likely modifiable[9], making it a potential target for promoting healthy aging and reducing the burden of age-related diseases across the lifespan.

In parallel, the field of aging research has seen rapid progress through the development of biological aging clocks derived from imaging and multi-omics data, like magnetic resonance imaging (MRIBAG[10,11]), plasma proteomics (ProtBAG[12]), and metabolomics (MetBAG[13]). These clocks aim to quantify the biological age of individuals across organ systems and molecular layers, enabling a more granular understanding of aging beyond chronological or calendar age. Organ-specific biological age gaps (BAGs) derived from these clocks have been used as intuitive and personalized biomarkers to quantify biological aging and have shown great predictive value for disease morbidity, cognition, and mortality risk[14,15]. This multi-organ, multi-omics aging clock framework offers a promising framework to model human health and disease in a systems-level and personalized manner.

Prior studies have demonstrated a nonlinear, U-shaped relationship between sleep duration and several phenotype-based aging clocks[16,17,18,19], suggesting that both short (e.g., <6 h) and long (e.g., >8 h) sleep may accelerate neurobiological aging. However, it remains unclear whether this relationship generalizes beyond the brain to body systems (i.e., multi-organ[20,21,22,23]) and omics layers (i.e., multi-omics[12,21]), and is similar in males and females. Do similar U-shaped patterns emerge in the structural, functional, and molecular hallmarks of aging in organs and tissues beyond the brain? Are these U-shaped patterns and the optimal sleep duration time consistent across sex and organs? To address these gaps, we leveraged large-scale population biobanks, combining both individual-level and summary-level data, consolidated through the MULTI study[20,13] (**Method 1** and **Supplementary Table 1**), to comprehensively map how sleep duration shapes biological aging across multiple systems and to elucidate the pathways through which disrupted sleep may drive age-related diseases and mortality. Our analysis focused on the UK Biobank's (UKBB) questionnaire-derived sleep duration (Field ID: 1160). While self-reported measures are inherently noisier than actigraphy, moderate correlations between self-reported and objective sleep measures[24,25] and the large sample size ($N\sim500,000$) enable robust detection of nonlinear patterns via generalized additive models (GAM; **Method 2**).

This study addresses several scientific and clinical questions. First, we examined the nonlinear, U-shaped associations between sleep duration and 23 multi-organ BAGs derived from multi-omics data (**Fig. 1**), and reinforced this pattern using *in vivo* imaging markers (**Extended Data Figure 1**) and circulating molecular phenotypes (plasma proteomics and metabolomics; **Extended Data Figure 2-3**). Secondly, we assessed whether abnormal sleep duration patterns (i.e., short or long sleep duration) were adversely associated with all-cause mortality and systemic diseases beyond the brain (**Fig. 2-3**). Thirdly, we examined whether short and long sleep duration are differentially associated with two distinct subtypes of LLD[8] through separate mediational pathways (**Fig. 4**). Finally, we explored whether sleep disturbances act as modifiable risk factors for disease (or genetic predisposition), consequences of disease burden, or reflect a potential bidirectional relationship (**Fig. 4**, **Extended Data Figure 4** and **Supplementary Note**

4). All results, code, and summary statistics are publicly available at the Sleep Chart portal: https://labs-laboratory.com/sleepchart.

Results

The U-shaped relationship between sleep duration and 23 multi-organ, multi-omics biological aging clocks

Using GAMs, we assessed the nonlinear, U-shaped relationship between sleep duration and 23 multi-organ, multi-omics BAGs (P<0.05/23; **Fig. 1**). We assessed the nonlinearity of the sleep-BAG association using the effective degree of freedom (EDF) as a proxy, which reflects the complexity of the smoothing term rather than the overall model fit to the mean outcome (**Method 2-3**).

We confirmed that 9 out of the 23 BAGs exhibited statistically significant nonlinear associations (P<0.05/23). Among the 9 ProtBAGs, the brain ProtBAG showed the strongest U-shaped association with sleep duration (EDF=3.61; $P_1 < 1 \times 10^{-20}$). At the population mean level, females exhibited significantly higher brain ProtBAG values than males ($P_2 < 1 \times 10^{-20}$). The interaction between sex and sleep duration approached nominal significance ($P_3 = 0.06$), indicating a potential trend toward sex-specific associations. We then estimated the optimal sleep duration based on the peak of the smoothed spline curves for the brain ProtBAG, identifying 7.82 hours for females and 7.70 hours for males. Similar U-shaped relationships were also evident for the pulmonary (EDF=3.21; $P_1 < 1 \times 10^{-20}$), hepatic (EDF=3.13; $P_1 < 1 \times 10^{-20}$), immune (EDF=3.47; $P_1 < 1.78 \times 10^{-5}$), and skin (EDF=3.21; $P_1 < 3.12 \times 10^{-6}$) ProtBAGs. Among the 5 MetBAGs, the endocrine MetBAG showed a significant U-shaped relationship (EDF=1.04; $P_1 = 3.97 \times 10^{-5}$), and the mean population value was different between females and males ($P_2 < 1 \times 10^{-20}$; $P_3 = 5.72 \times 10^{-7}$), with the estimated optimal sleep duration being 6.67 hours for females and 6.06 hours for males. Finally, among the 7 MRIBAGs, the brain MRIBAG showed the most significant U-shaped relationship (EDF=1.94; $P_1 = 3.85 \times 10^{-7}$), and the mean population value was different between females and males ($P_2 = 1.88 \times 10^{-11}$; $P_3 = 0.96$). The optimal sleep time was 6.48 hours for females and 6.42 hours for males. Significant signals were also observed for the adipose (EDF=1.93; $P_1 = 8.42 \times 10^{-4}$) and pancreas (EDF=1.95; $P_1 = 9.95 \times 10^{-6}$) MRIBAGs. Detailed statistics, including the P value, optimal family distribution, and EDF, are presented in **Supplementary Table 2**.

Several sensitivity analyses were performed. **Supplementary Figure 1** displays Quantile-Quantile (QQ) plots and residual vs. fitted (RVF) plots for the best model of each BAG. **Supplementary Figure 2-3** and **Supplementary Table 3** present split-sample, age-stratified analyses and the GAMLSS[26] approach to scrutinize the robustness of the U-shaped pattern. **Supplementary Figure 4** shows a potential replication of the U-shaped relationship in an independent dataset[27,28], though the sample size (*N*=573) is significantly smaller than that of UKBB (*N*=500k). We also observed this U-shaped pattern between sleep duration and 720 organ-specific imaging-derived phenotypes (**Extended Data Figure 1**), 342 organ-enriched plasma proteins (**Extended Data Figure 2**), and 107 organ-associated plasma metabolites (**Extended Data Figure 3**, **Method 4-6**, and **Supplementary File 1-3**). A detailed discussion of these results and their implications in sleep-related hypotheses is presented in **Supplementary Note 1**.

Overall, among the 9 significant sleep-BAG associations, the optimal sleep duration for females was 6.5 to 7.8 hours, and for males was 6.4 to 7.7 hours. Based on this, we defined normal sleep duration as 6 to 8 hours [6-8] for subsequent genetic and time to incident disease predictive analyses. Although our definition is data-driven by the optimal range observed, it is important to note that the definition of normal sleep varies between studies and is often influenced by cultural and environmental factors[29]. We also performed a sensitivity analysis for

time to incident disease prediction using [7-9] hours as normal sleep duration (**Supplementary Figure 6**), as suggested by the National Sleep Foundation[30] for young/older adults.

To summarize, we observed robust U-shaped associations between sleep duration and multi-organ BAGs, extending beyond the brain to organ systems such as the pulmonary, hepatic, and immune systems. This U-shaped pattern was subsequently confirmed in *in vivo* imaging-derived phenotypes, plasma proteins, and metabolites. Given strong evidence of the U-shaped relationship across widespread biomarkers at both phenotypic and molecular levels, we classified sleep duration into short (<6 hours), long (>8 hours), and normal ([6–8] hours) categories for all downstream analyses.

Figure 1: **Sleep Chart delineates U-shaped patterns between sleep duration and biological aging clocks**

Sleep duration (x-axis) exhibits nonlinear U-shaped relationships with 9 out of 23 BAGs across 17 organs and 3 omics types (y-axis; units are normalized years): 11 ProtBAGs[12] for plasma proteomics, 5 MetBAGs[13] for plasma metabolomics, and 7 MRIBAGs[10] for *in vivo* MRI data. For each BAG, we fitted a generalized additive model (GAM) with cubic regression splines to assess the nonlinear association between sleep duration and BAG, stratified by sex and sex-sleep interaction term. The solid curves depict estimated BAG, while shaded bands represent the 95% confidence interval (CI). For significant signals (P<0.05/23) with colored icons and the * symbol, optimal sleep duration minimizing each BAG is displayed separately for males and females.

Long and short sleep duration are associated with systemic diseases beyond the brain and all-cause mortality

Our genome-wide association study (GWAS; **Method 7**) identified 5 genetic loci (P<5x10^{-8}) associated with abnormal sleep duration patterns (**Fig. 2a**). A locus at 3q29 (top lead SNP: rs34382732) was associated with short sleep duration, whereas long sleep duration was linked to loci at 2q13 (rs62158206), 11q13.5 (11:76414249_GT_G), 11q23.3 (rs75458655), and 17q21.31 (rs62061734), highlighting potential genetic heterogeneity between short and long sleep patterns. We denoted the genomic loci using their top lead SNPs defined by FUMA (**Supplementary Note 2**), considering linkage disequilibrium; the genomic loci are presented in **Supplementary Table 4**. The Manhattan plot and QQ plot, as well as the LDSC[31] intercept, are presented in **Supplementary Figure 5**. We then conducted gene-property analyses[32] to assess tissue-specific expression patterns of genetic signals associated with short and long sleep duration, using gene expression data from 54 human tissues provided by GTEx v8[33]. Notably, only the genetic architecture of short sleep duration demonstrated significant enrichment (P$_{FDR}$<0.05) in several brain regions, including the cerebellum, caudate, and hippocampus (**Fig. 2b**), but not long sleep duration.

Given the relatively smaller number of genomic loci in our GWASs, despite the large sample size (N > 300,000), we hypothesize that the U-shaped association between sleep duration and BAG is primarily environmentally driven and modifiable. As such, we hypothesized that this U-shaped pattern observed at the BAG level to be flattened and attenuated when examining BAG polygenic risk scores (PRS) derived in our previous studies[10,11,12,13]. Our results supported our hypothesis (**Extended Data Figure 4**). Notably, the endocrine MetBAG showed a J-shaped association, with higher genetic risk in individuals reporting shorter sleep duration, while the metabolic MetBAG demonstrated a linear inverse relationship, indicating lower PRS with longer sleep. Additional support was from genetic correlation analyses, which revealed only a significant positive correlation between short sleep duration and endocrine MetBAG, and between long sleep duration and pancreas MRIBAG (P < 0.05/23) (**Supplementary Table 5**). These findings imply that while most sleep-BAG relationships are not genetically mediated, certain organ systems, particularly endocrine and metabolic pathways, may share partial genetic underpinnings with habitual sleep duration.

Genetic correlation analyses revealed 153 positive associations between abnormal sleep duration patterns and systemic diseases across multiple organ systems (P<0.05/527), dominated by short sleep duration (**Fig. 2c**). For short sleep duration, we observed robust correlations with cardiovascular diseases (e.g., ischemic heart disease [I9_IHD], heart failure [I9_HEARTFAIL], coronary atherosclerosis [I9_CORATHER]), metabolic disorders (e.g., type 2 diabetes [T2D_WIDE], insulin-requiring diabetes [KELA_DIAB_INSUL_EXMORE]), and musculoskeletal conditions (e.g., low back pain [M13_LOWBACKPAIN], osteoarthritis [M13_ARTHROSIS_INCLAVO], soft tissue disorders [M13_SOFTTISSUE]). Neurological and psychiatric associations included migraine [G6_MIGRAINE], depression [F5_DEPRESSION_DYSTHYMIA], anxiety [F5_ANXIETY], substance use disorders [KRA_PSY_SUBSTANCE_EXMORE], and suicidality [VWXY20_SUICI_OTHER_INTENTI_SELF_H], indicating broad involvement of the central nervous system. Pulmonary and infectious conditions (e.g., asthma [J10_ASTHMA_MAIN_EXMORE], bronchitis [BRONCHITIS], COPD [J10_COPD]) were also genetically correlated, as were gastrointestinal and hepatic diseases (e.g., reflux [K11_REFLUX], diverticulosis [K11_DIVERTIC], IBS [K11_IBS]). In contrast, long sleep

duration showed a more focused genetic correlation profile, predominantly involving brain-related phenotypes, such as major depressive disorder [F5_DEPRESSIO], schizophrenia [SCZ], bipolar disorder [BIP], alcohol dependence [F5_ALCOHOL_DEPENDENCE], ADHD [ADHD], and migraine [G6_MIGRAINE_NO_AURA], suggesting potential compensatory or indirect neuropsychiatric mechanisms (further elucidated in **Fig. 4**). **Supplementary File 4** present detailed staitsics for our genetic correlation analysis.

Taken together, these findings support that short and long sleep duration have distinct genetic architectures from each other (**Fig. 2a**). While both show genetic correlations with various systemic diseases, short sleep duration exhibits broader systemic associations, whereas long sleep duration is more specifically linked to brain-related traits (**Fig. 2c**).

Figure 2: **Genetic evidence for a systemic landscape of abnormal sleep duration patterns compared to normal sleep duration**

a) Cytogenetic regions associated with short ([4–6] hours hours) and long sleep duration ((8–10] hours) compared to a normal sleep duration ([6-8] hours), with significant genomic loci identified using the genome-wide significance threshold (P-value<5x10^{-8}). **b**) MAGMA gene

property analysis of tissue-specific expression across 54 GTEx v8 tissues. Statistical significance was determined using FDR-adjusted P-values. **c**) Genetic correlation estimates via LDSC between the two abnormal sleep duration patterns and 527 disease endpoints from FinnGen and PGC (P-value<0.05/527). An online interactive webpage is available at https://labs-laboratory.com/sleepchart/sleep_gc.html to facilitate visualization.

Leveraging ICD code-based clinical diagnosis and echoing the genetic correlation results, we further assessed the relationships between abnormal sleep duration patterns and the time to incident disease prediction, as well as all-cause mortality, using a survival analysis framework (**Method 8**). We identified 153 significant associations between sleep duration patterns (both short and long) and disease endpoints (P<0.05/726), after correcting for multiple comparisons across endpoints with at least 50 cases (**Fig. 3a**), with a notable predominance of associations linked to short sleep duration (1.20<hazard ratio<6.96). These findings span multiple organ systems, supporting the systemic and direct association with disturbed sleep. Within the brain-related disorders, short sleep was significantly associated with depressive episodes (F329), anxiety disorders (F419), and primary insomnia (G473), reinforcing the well-established link between sleep and mental health. In the metabolic domain, we observed associations with obesity (E669), type 2 diabetes (E119), and hyperlipidemia (E780), aligning with prior evidence that short sleep disrupts metabolic homeostasis. Cardiovascular outcomes such as essential hypertension (I10), ischemic heart disease (I209, I252), and arrhythmias (I471, I440) were also enriched, suggesting increased cardiovascular risk among individuals with short sleep. Pulmonary conditions, including chronic obstructive pulmonary disease (J449) and asthma (J459), were linked to both short and long sleep, though more strongly with short sleep. Finally, a cluster of digestive disorders, including gastritis and duodenitis (K297), gastroesophageal reflux disease (K219), and functional intestinal disorders (K590), was significantly predicted by disturbed sleep duration. These findings underscore the broad biological associations of both insufficient and prolonged sleep, highlighting distinct mechanistic pathways by which short and long sleep duration relate to systemic disease endpoints (further elucidated in **Fig. 4**). We also conducted a sensitivity analysis using 7–9 hours as the definition of normal sleep duration and successfully replicated all significant associations (**Supplementary Figure 6**).

In predicting all-cause mortality, we found that both short (hazard ratio=1.50 [1.44, 1.55]; $P<1\times10^{-20}$) and long sleep duration (hazard ratio=1.40 [1.36, 1.44]; $P<1\times10^{-20}$) patterns were positively associated with increased risk of death from any cause (**Fig. 3b**). **Supplementary File 5** presents detailed statistics for all survival analyses. **Supplementary Note 3**, **File 6**, and **Extended Data Figure 5** present an independent validation analysis using the TriNetX dataset, examining the associations between two sleep disorders (insomnia and hypersomnia as proxies for short and long sleep duration) and the disease endpoints identified in **Fig. 3a**, as well as all-cause mortality.

Figure 3: **Clinical evidence for a systemic involvement of abnormal sleep duration patterns compared to normal sleep duration**

a) Using normal sleep duration, [6-8] hours, as the reference, we treated sleep duration patterns as categorical variables ([4–6) hours for short sleep, and (8–10] hours for long sleep) to estimate their association with 726 comorbidity-free disease endpoints defined by ICD-10 codes (limited to diseases with more than 50 cases). After applying Bonferroni correction for multiple

comparisons (P< 0.05/726), we highlight the significant associations and annotate representative systemic diseases across various organ systems. **b**) Short and long sleep duration are associated with a higher risk of all-cause mortality. An online interactive webpage is available at https://labs-laboratory.com/sleepchart/sleep_cox.html to facilitate visualization.

Distinct mediating pathways from short or long sleep duration to disease endpoints in late-life depression via biological aging burden

Given that short sleep duration showed more significant associations with systemic disease endpoints in our genetic correlation (**Fig. 3a**) and survival analysis (**Fig. 3b**) than long sleep duration, we hypothesize that long sleep may be linked to disease risk through more complex or indirect pathways, potentially serving as a marker of underlying health conditions or reflecting mediational, compensatory physiological responses rather than acting as a direct risk factor (**Method 9**).

To evaluate this hypothesis, we performed structural equation modeling (SEM) using sleep duration patterns (short or long) as exposures, the 7 MRIBAGs as mediators, and two AI- and MRI-derived subtypes of late-life depression (LLD1 and LLD2[8]) as outcomes. We selected LLD as the outcome because it is closely linked to sleep disturbances (**Fig. 2-3**) and aging, making it a compelling model to explore potential mediating pathways. In the pathway linking short sleep to LLD1, characterized by preserved subcortical brain volume, we observed strong direct effects (c_2 ranging from -0.33 to -0.24) across 6 organ systems. Among the mediators, only the adipose MRIBAG showed a significant indirect effect ($a_1=0.44\pm0.13$; $c_1=-0.05\pm0.005$), suggesting a specific role for adipose aging in mediating this relationship. In contrast, for long sleep, the associations with LLD1 were predominantly mediated through organ-specific MRIBAGs, particularly the brain ($a_1=0.54\pm0.08$; $c_1=0.11\pm0.002$) and adipose ($a_1=0.61\pm0.09$; $c_1=-0.04\pm0.005$) pathways. Notably, brain MRIBAG alone accounted for 62% of the total effect via mediation, followed by the adipose and liver MRIBAGs (24%), highlighting a more indirect and organ-mediated link between long sleep and late-life depression. Similar patterns were observed for LLD2, which was characterized by a diffuse pattern of cortical atrophy in LLD (**Fig. 4**). All statistics for the mediation analyses are presented in **Supplementary File 7**.

Our mediation analysis positioned sleep duration (exposure variable) as a modifiable risk factor based on the time-ordering of the data collection, where sleep data were collected at baseline, and MRI was collected in follow-up visits. As shown in **Supplementary Table 6**, we present additional sensitivity analyses in which brain MRIBAG and LLD1/2 were alternately specified as mediators and outcomes. Of note, we could not entirely rule out the possibility that sleep disturbances might be consequences of disease burden based on the current data time-ordering constraint using SEM. Alternatively, we used Mendelian randomization to test this inverse causal relationship from disease endpoints to sleep duration. As shown in **Supplementary Note 4** and **File 8**, Mendelian randomization analyses did not support a causal relationship from the 525 disease endpoints (as exposure variables from FinnGen and PGC) to the 2 binary sleep traits when treated as outcome variables. These findings further support the notion that sleep disturbances may act as risk factors for disease endpoints, though potential bidirectional relationships cannot be fully excluded.

Our mediation analysis treated sleep duration as a modifiable risk factor, based on the temporal sequence of data collection: sleep data were recorded at baseline, while brain MRI occurred during follow-up. As detailed in **Supplementary Table 6**, we conducted sensitivity analyses by alternately specifying brain MRIBAG and LLD1/2 as mediators and outcomes.

However, due to the limitations of the data's time-ordering, we cannot fully exclude the possibility that sleep disturbances result from underlying disease burden. To test this, we conducted Mendelian randomization analyses (**Supplementary Note 4** and **File 8**) to test the reverse causal pathway, from 525 disease endpoints (using FinnGen and PGC data) to the 2 binary sleep traits. These analyses did not support a widespread causal effect of disease on sleep, reinforcing the interpretation of sleep disturbances as potential risk factors. Still, we acknowledge the possibility of bidirectional effects[34,35].

Figure 4: **7 MIRBAGs mediate the effects of disturbed sleep duration patterns on 2 late-life depression subtypes**

We tested whether 7 MRIBAGs mediate the effect of abnormal sleep duration on two AI-derived subtypes of late-life depression (LLD1 and LLD2[8]). Participants were grouped into short (4-6 hours), normal ([6–8] hours; reference), and long (8-10 hours) sleep categories: sleep duration→ MRIBAG→LLD1/2. For each LLD subtype and each contrast (short vs. normal, long vs. normal), we fit structural equation models (SEMs) using the *lavaan* package in R. The model included a direct path from the binary-coded sleep category to the LLD subtype (depicted as solid lines with warm colors) and indirect paths mediated through the MRIBAG (shown as dotted lines with cool colors). Only statistically significant pathways (P < 0.05/7) and estimated path coefficients are displayed. All models were adjusted for relevant covariates, including age,

sex, body mass index, and systolic and diastolic blood pressure, among others. Standardized estimates were obtained using 1,000 nonparametric bootstrap resamples. **a**) Mediational models for short sleep duration→MRIBAG→LLD1. **b**) Mediational models for long sleep duration→MRIBAG→LLD1. **c**) Mediational models for short sleep duration→MRIBAG→LLD2. **d**) Mediational models for long sleep duration→MRIBAG→LLD2. Our primary analyses were based on the temporal ordering of data collection, with sleep duration assessed at baseline and both MRIBAG and LLD subtypes measured at the second visit.

Discussion

In this study, we reveal a robust and systemic U-shaped association between sleep duration and biological aging across multiple organ systems and omics layers. By leveraging large-scale, multimodal data from the MULTI study, we demonstrate that both short (<6 hours) and long (>8 hours) sleep duration are consistently linked to elevated biological aging burden across 7 organ systems and 3 omics types. Importantly, our findings extend prior work on phenotype-based aging clocks by showing that this nonlinear sleep-aging relationship generalizes across the body and is evident not only in structural and functional imaging features but also at the molecular level. This is the first study, to our knowledge, to reveal a broad agreement between sleep duration and multi-organ, multi-omics aging clocks, and to link these signatures to systemic disease outcomes and mortality risk. Our results underscore the systemic biological adverse associations of disturbed sleep and provide a compelling framework for more targeted and thoughtful attention to sleep disturbance as a potential signal of emerging health issues and a partner in the quest to promote healthy aging, reduce disease risk, and extend lifespan.

U-shaped pattern between sleep duration and biological aging clocks beyond the brain
A key contribution of this study lies in uncovering consistent U-shaped associations between sleep duration and organ-specific biological aging clocks across diverse organs, tissues, and omics data types. At the molecular level, we observed that both short and long sleep duration are associated with accelerated pulmonary, brain, hepatic, immune, and skin ProtBAGs, suggesting that proteomic signatures of aging in these systems are particularly sensitive to sleep perturbations. These findings support sleep's systemic implications on immune-inflammatory processes[36,37,38], metabolic detoxification[39,40], and neurodegenerative pathways[41]. Notably, endocrine MetBAG also exhibited a U-shaped pattern, highlighting the metabolic cost of sleep imbalance, possibly via dysregulation of hormonal homeostasis and glucose metabolism[42,43]. At the imaging level, U-shaped patterns in brain MRIBAG, adipose MRIBAG, and pancreas MRIBAG further reinforce the idea that both central and peripheral organs experience structural and functional alterations under sleep extremes[44,45,46].

In addition to the overarching U-shaped pattern, our results reveal organ- and omics-specific variability in the optimal sleep duration associated with minimal BAG (i.e., the lightest aging burden). While the overall optimal sleep range centered between 6 and 8 hours per night, consistent with prior epidemiological recommendations[4], the precise inflection point varied across tissues and omics types. For instance, brain ProtBAG showed the lowest aging burden around 7.7 hours of sleep, whereas brain MRIBAG reached its inflection point closer to 6.5 hours. These findings suggest that molecular aging in the brain may require longer restorative sleep than its structural counterpart, potentially reflecting the different timescales and mechanisms by which proteomic versus imaging phenotypes capture sleep-related damage or resilience[45,47]. Alternatively, this can be due to a reverse causality, where longer sleep reflects brain aging rather than causes it, pulling the right side of the U-shaped curve upward, and making the apparent optimal sleep duration appear shorter for the brain MRIBAG (e.g., 6.5 hours). Moreover, clear sex differences emerged in the relationship between sleep and biological aging. Several organs displayed significant BAG-by-sex interactions and divergence in the population mean and optimal sleep time per night. These differences may reflect sex-specific hormonal regulation, immune responses, activity patterns, or metabolic demands, as well as social unfavorable factors for females, that influence how sleep duration modulates aging

trajectories across organ systems – a concept supported by growing literature on sex-specific sleep physiology and aging biology[48,49,50].

Together, these results reveal that deviations from optimal sleep duration are not only associated with the brain but also peripheral tissues and systems critical to cardiometabolic and immune regulation, emphasizing the multi-organ biological burden imposed by disrupted sleep.

Evidence from molecular factors and imaging-derived phenotypes reinforces the U-shaped pattern of sleep duration

Our findings provide converging evidence from imaging, proteomics, and metabolomics that support the hypothesis that sleep duration exerts nonlinear effects across multiple organ systems and molecular domains. These patterns reflect the systemic nature of sleep physiology and are consistent with prior research showing that both sleep deprivation and prolonged sleep are associated with adverse outcomes across diverse biological pathways.

At the imaging level, U-shaped associations between sleep duration and organ-specific IDPs, particularly in the brain, adipose tissue, and pancreas, echo prior findings that link both short and long sleep with structural brain alterations and metabolic dysregulation (**Extended Data Figure 1**). For example, previous neuroimaging studies have shown that hippocampal atrophy is associated with both insufficient and excessive sleep, possibly reflecting neurotoxic or neurodegenerative processes triggered by circadian misalignment, impaired glymphatic clearance, or inflammatory load[44,45]. Similarly, adipose tissue dysfunction and pancreatic abnormalities underlie cardiometabolic conditions such as insulin resistance and obesity, both of which have been associated with extremes of sleep[51,52].

At the molecular level, the U-shaped relationships observed in organ-enriched plasma proteins align with several established biological hypotheses of sleep regulation (**Extended Data Figure 2**). For instance, immune-enriched proteins involved in neutrophil chemotaxis, complement activation, and leukocyte signaling were significantly altered in individuals with suboptimal sleep. This supports the immune activation hypothesis, positing that sleep disturbances lead to, or reflect, systemic inflammation, impairing tissue repair, neurogenesis, and metabolic homeostasis[53]. Similarly, hepatic-enriched proteins involved in coagulation and innate defense pathways reinforce the liver-sleep axis, wherein disrupted sleep contributes to liver stress, oxidative damage, and altered lipid metabolism[54]. Complementing these proteomic findings, the metabolomics results revealed alterations in metabolites involved in fatty acid metabolism, ketone body synthesis, and amino acid catabolism (**Extended Data Figure 3**). For example, the observed enrichment of pathways related to neurotransmitter transport and synaptic remodeling, such as tyrosine metabolism and $Na\square/Cl\square$-dependent transporter activity, supports the neurochemical plasticity hypothesis, suggesting that sleep modulates central nervous system function via fine-tuned molecular and ionic gradients essential for neural signaling[55,56,57].

Altogether, our multi-layered findings reinforce the notion that sleep duration is not only a behavioral or neurological variable but a deeply embedded systemic modulator. The evidence from both structural-functional imaging and circulating biomolecules converges to support the role of sleep in maintaining organ integrity, metabolic balance, and immune equilibrium. These results further reinforce sleep as an important process with far-reaching molecular and physiological implications across the body.

Genetic and clinical evidence to support abnormal sleep duration patterns affecting systemic disease endpoints and mortality

Our integrated genetic and clinical analyses consistently demonstrate that disturbed sleep duration patterns, both short and long, are robustly linked to a wide array of systemic disease endpoints and increased mortality risk. Genetic correlation analyses revealed significant positive associations between abnormal sleep duration patterns and over 150 disease phenotypes across cardiovascular, metabolic, musculoskeletal, psychiatric, neurological, pulmonary, and gastrointestinal systems, with short sleep duration exhibiting particularly widespread effects. These patterns were mirrored in our clinical survival analyses, where short and long sleep duration were both significantly associated with elevated hazard ratios for a broad spectrum of diseases and all-cause mortality. Importantly, the genetic and clinical evidence together suggest that short and long sleep duration may contribute to disease via distinct biological pathways: short sleep duration appears to exert more direct effects across multiple organ systems, potentially reflecting heightened physiological stress and systemic dysregulation, whereas long sleep duration shows a more focused association with neuropsychiatric and brain-related phenotypes, potentially reflecting compensatory mechanisms or underlying latent pathologies. These findings reinforce the role of sleep as a potentially modifiable risk factor in health and aging management and underscore the need for mechanistically informed strategies tailored to sleep disruption, as we further illustrated in LLD.

Distinct mechanistic insights into short sleep duration and long sleep duration patterns impact late-life depression

While LLD has been conceptualized as a brain-centric disorder, our findings suggest a more nuanced framework in which both short and long sleep duration shape LLD vulnerability via distinct mechanistic pathways involving multiple organ systems. Notably, short sleep duration appears to exert more direct effects on LLD. This pattern may reflect acute physiological stressors associated with sleep deprivation, including heightened sympathetic activity, immune dysregulation, and hypothalamic-pituitary-adrenal axis activation, all of which can influence mood regulation independently of brain atrophy. These findings are consistent with prior studies linking short sleep to systemic inflammation, metabolic strain, and emotional dysregulation[53,58], pointing to a fast-acting, body-to-brain pathway[59].

In contrast, long sleep duration appears to be associated with LLD predominantly through indirect pathways, especially via accelerated aging in the brain and adipose tissue. The strong mediation effects observed for brain and adipose MRIBAGs suggest that long sleep may not be a direct risk factor per se, but rather a marker of underlying physiological compensations or subclinical disease processes, potentially including neurodegeneration, energy imbalance, or immune exhaustion, that gradually erode mental health resilience. Such patterns support emerging views of long sleep as a complex, sometimes maladaptive response to latent morbidity rather than a simple behavioral choice[60,61]. The pronounced mediational roles of brain and other body aging clocks are particularly striking, indicating that central and systemic aging may jointly drive mood vulnerability in individuals with prolonged sleep. Importantly, the mediation of long sleep's effect on depression was not exclusive to the brain, despite LLD's traditional classification as a neuropsychiatric disorder. This broader multi-organ involvement suggests that depression in late life might arise from distributed physiological aging, wherein systemic decline in tissues like adipose, liver, or cardiovascular systems contributes to or exacerbates neural vulnerability. This is in line with recent multidimensional models of depression that integrate metabolic dysfunction, systemic inflammation, and neuroplasticity deficits as co-occurring drivers of depressive phenotypes[62,63]. Importantly, we used Mendelian randomization to partially

rule out the possibility of reverse causality, whereby sleep disturbances may be caused by disease burden. While a previous study reported a bidirectional relationship between sleep disturbances and major depressive disorder, their analysis relied on a lenient P-value threshold (P<0.0125) for selecting instrumental variables, which may cause weak instrument bias[64].

Together, these findings highlight that while short sleep may acutely disturb mood through direct neuroimmune and neuroendocrine perturbations, long sleep's influence may reflect an organ-mediated pathway, linking chronic subclinical aging processes to eventual neuropsychiatric decline. This distinction reinforces the need for tailored sleep interventions and underscores the importance of viewing LLD as a systemic, not merely cerebral, manifestation of aging.

Limitations

Several limitations warrant consideration. First, although our findings revealed U-shaped associations between sleep duration and various phenotypes, these patterns require external validation in independent cohorts, potentially on the same scale as UKBB. Second, the reliance on self-reported, questionnaire-based sleep duration measurement may introduce recall bias or misclassification, and future studies incorporating objective measures such as actigraphy are essential to confirm these associations. Third, the cross-sectional design of this study limits our ability to determine causality or the direction of effect; although our current analysis positions sleep disturbance as a modifiable risk factor, longitudinal follow-up is needed to clarify whether sleep disturbance is a modifiable risk factor or a consequence of disease burden. Fourth, our analyses were restricted to individuals of predominantly European ancestry, which limits generalizability. Studies in more ethnically diverse and underrepresented populations are needed to ensure broader applicability. Fifth, despite adjusting for a wide array of covariates, residual confounding and the potential for reverse causality, particularly for long sleep as a marker of subclinical illness, cannot be fully excluded. Sixth, future research needs to extend the Sleep chart across the lifespan to better capture dynamic patterns of sleep duration beyond adults. Finally, while our analyses support the interpretation of sleep disturbance as a modifiable risk factor and provide no evidence for reverse causality based on Mendelian randomization, further investigation using longitudinal data is warranted to rigorously assess this relationship.

Methods

Method 1: The MULTI study

The MULTI study is an ongoing initiative to integrate and consolidate multi-organ data and multi-omics data, including imaging, genetics, and proteomics. Building on existing consortia and studies, MULTI aims to curate and harmonize the data to model human aging and disease at scale across the lifespan. Refer to **Supplementary Table 1** for comprehensive information, including the complete list of data analyzed and their respective sample characteristics. Participants provided written informed consent to the corresponding studies. The MULTI study is approved by the Institutional Review Board at Columbia University (AAAV6751).

UK Biobank

UKBB[65] is a population-based research initiative comprising around 500,000 individuals from the United Kingdom between 2006 and 2010. Ethical approval for the UKBB study has been secured, and information about the ethics committee can be found here: https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/governance/ethics-advisory-committee. The main sleep data used in this study were sleep duration (Field ID: 1160) based on a self-reported questionnaire collected from all 500,000 participants at baseline. The 7 brain MRIBAGs were derived from multi-organ MRI data at the second visit, 11 ProtBAGs, and 5 MetBAGs were derived using plasma proteomics and metabolomics at baseline. Finally, we also included individual plasma proteins and metabolites in our ProWAS and MetWAS, as detailed below.

FinnGen

The FinnGen[66] study is a large-scale genomics initiative that has analyzed over 500,000 Finnish biobank samples and correlated genetic variation with health data to understand disease mechanisms and predispositions. The project is a collaboration between research organizations and biobanks within Finland and international industry partners. For the benefit of research, FinnGen generously made their GWAS findings accessible to the wider scientific community (https://www.finngen.fi/en/access_results). This research utilized the publicly released GWAS summary statistics (version R9), which became available on May 11, 2022, after harmonization by the consortium. No individual data were used in the current study.

FinnGen published the R9 version of GWAS summary statistics via REGENIE software (v2.2.4)[67], covering 2272 DEs, including 2269 binary traits and 3 quantitative traits. The GWAS model encompassed covariates like age, sex, the initial 10 genetic principal components, and the genotyping batch. Genotype imputation was referenced on the population-specific SISu v4.0 panel. We included GWAS summary statistics for 521 FinnGen DEs in our analyses.

Psychiatric Genomics Consortium

PGC[68] is an international collaboration of researchers studying the genetic basis of psychiatric disorders. PGC aims to identify and understand the genetic factors contributing to various psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and others. The GWAS summary statistics were acquired from the PGC website (https://pgc.unc.edu/for-researchers/download-results/), underwent quality checks, and were harmonized to ensure seamless integration into our analysis. No individual data were used from PGC. Each study detailed its specific GWAS models and methodologies, and the consortium

consolidated the release of GWAS summary statistics derived from individual studies. In the current study, we included summary data for 6 brain diseases.

TriNetX

To evaluate real-world clinical outcomes associated with sleep traits, we leveraged the TriNetX[69] database (https://trinetx.com/), a global federated health research platform that provides access to de-identified electronic medical records from over 70 healthcare organizations, encompassing more than 90 million patients. The TriNetX platform integrates clinical data, including diagnoses, medications, procedures, and laboratory results, enabling large-scale observational analyses. We utilized this resource to assess associations between sleep (using insomnia and hypersomnia as proxies for short and long sleep duration) and systemic disease outcomes across organ systems identified in UKBB (**Fig. 3**).

The Multi-Ethnic Study of Atherosclerosis

The Multi-Ethnic Study of Atherosclerosis (MESA[27,28]) is a medical research initiative involving over 6,000 men and women from six U.S. communities. For this analysis, we included 573 participants with available brain MRI data, sleep duration measures, and relevant covariates such as age, sex, and BMI. We leveraged the MESA cohort to attempt replication of the U-shaped association observed in UKBB for the brain MRIBAG.

Method 2: GAM models the relationship between sleep duration and organ aging clocks, IDPs, proteins, and metabolites

To model the nonlinear association between sleep duration and the 23 multi-organ BAGs and any other phenotype, we implemented GAMs using the *mgcv* package in R. This approach enabled flexible modeling of complex relationships, whether linear, flat, sigmoidal, or U-shaped, without requiring any prior assumptions about the underlying shape of the fitted curves. We adjusted for key demographic and physiological covariates (i.e., age, sex, weight, height, waist circumference, BMI, diastole, assessment center, and systolic blood pressure, time differences for data collection, disease status). Participants reporting extremely short durations or those with missing sleep duration were excluded. The analysis was restricted to those reporting 4-10 hours of sleep to reduce influence from outliers. For each BAG, we fitted GAM with cubic regression splines (*bs='cr'*) to smooth the nonlinear association between sleep duration and the BAG, considering sex and sex-sleep interaction term.

      Model selection was performed by evaluating combinations of smoothing dimensions (*k*=3, 5, 10, 15, 20) and distribution families (i.e., Gaussian, t-distribution, and gamma distribution), with the optimal model chosen based on the lowest Akaike information criterion. We tested *i*) the main effect (sleep duration; P_1), *ii*) sex difference in population mean (P_2), and *iii*) sex-sleep interaction terms (P_3) on each BAG. The solid curves in **Fig. 1** depict estimated BAG, while shaded bands represent the 95% confidence interval (CI). **Supplementary Figure 1** provides diagnostic plots of model fit for the optimal model. The raw BAG values were normalized to the range (0, 1) to allow for the application of different family distributions in the model.

Method 3: 23 Multi-organ aging clocks

In our previous work, we processed raw brain MRI data from the UK Biobank to extract 119 gray matter (GM) regions of interest (ROIs) from T1-weighted images, which were used to

compute the brain MRIBAG. For the heart MRIBAG, we utilized 80 cardiac MRI-derived traits from Bai et al.[20], which we had incorporated in an earlier study. Additionally, five abdominal MRIBAGs were derived from abdominal MRI data (Category ID = 105) across multiple studies[70,71,72,73,74,75], yielding a total of 7 MRIBAGs. We also developed 11 ProtBAGs using UKBB plasma proteomics data[12], along with 5 MetBAGs[10] based on plasma metabolomics profiles. All 23 BAGs were developed using a nested cross-validation framework, adhering to best practices in machine learning to minimize overfitting and prevent data leakage[76,12].

Method 4: IDP-wide associations
We assessed the association between sleep duration and 720 image-derived phenotypes (IDPs) covering 8 organ systems and tissues using UKBB *in vivo* imaging data. For each IDP, we fitted the same GAM as in **Method 2** to capture the nonlinear associations with sleep duration. These models included age, sex, body mass index, height, weight, waist circumference, assessment center, blood pressure, and disease status as covariates. Additionally, organ-specific covariates were incorporated, such as brain positioning in the scanner (lateral, transverse, and longitudinal), head motion, and intracranial volume for the brain IDPs. Outlier values in the IDP outcome variables, defined as ±4 standard deviations from the mean, were removed to minimize the influence of extreme values. For each IDP, we extracted effect estimates and tested for main effects of sleep, sex differences, and sex-specific interactions. Predicted curves and 95% confidence intervals were generated separately for males and females. When significant ($P<0.05/720$), sex-specific turning points (optimal sleep duration) were also identified from the fitted curves. Descriptions of these 720 IDPs are provided in our previous study[10,11,15] and **Supplementary File 1**.

Method 5: Proteome-wide associations
We used the original dataset (Category code: 1838), which was analyzed and shared with the research community by the UKB-PPP[77]. The initial quality control procedures were described in the original study[78], and we implemented additional quality control steps as outlined below. Our analysis focused on the first instance of the proteomics data ("instance" = 0). We then integrated Olink files containing coding information, batch numbers, assay details, and limit of detection (LOD) data (Category ID: 1839) by matching them to the proteomics dataset ID. Finally, we excluded Normalized Protein eXpression (NPX) values that fell below the protein-specific LOD. Descriptions of these proteins are provided in our previous study[12] and **Supplementary File 2**.

We conducted ProWASs by linking sleep duration to 2923 unique plasma proteins measured using the same GAM model. The GAM was adjusted for common covariates, including age, sex, weight, height, waist circumference, BMI, assessment center, disease status, diastolic and systolic blood pressure, protein batch number, limit of detection, and the first 40 genetic principal components. Multiple testing corrections were applied using Bonferroni adjustment ($P < 0.05/2923$). To identify and exclude extreme outliers, we defined an upper threshold as the mean plus 4 times the standard deviation for each protein. We mainly focus on the 342 organ-enriched proteins defined in our previous study[12].

Method 6: Metabolome-wide associations
We used the original data (Category ID: 220), which were analyzed and made available to the community by Nightingale Health Plc. The original data were *i*) calibrated absolute concentrations (or ratios) and not raw NMR spectra, and *ii*) before release, had already been

subject to quality control procedures by Nightingale Health Plc[79]. Following the additional procedures described in Ritchie et al.[80], we performed additional quality check steps to remove a range of unwanted technical variations, including shipping batch, 96-well plate, well position, aliquoting robot, and aliquot tip. We focused our analysis on the first instance of the metabolomics data ("instance"=0). The analysis included 327 metabolites (comprising both small molecules and lipoprotein measures), of which 107 were non-derived metabolites and the remainder were composite metabolites, across 274,247 participants. Descriptions of these metabolites are provided in our previous study[13] and **Supplementary File 3**.

We conducted MetWASs by linking sleep duration to 327 plasma metabolites. The GAM controlled common covariates, including age, sex, weight, height, waist circumference, BMI, assessment center, disease status, diastolic and systolic blood pressure, and the first 40 genetic principal components. Multiple testing corrections were applied using Bonferroni adjustment ($P < 0.05/327$). To identify and exclude extreme outliers, we defined an upper threshold as the mean plus 4 times the standard deviation for each metabolite. We mainly focus on the 107 organ-associated metabolites defined in our previous study[13].

Method 7: Genetic analyses

We used the genotype and imputed genotype data from UKBB for all genetic analyses. Our quality check pipeline focused on European ancestry in UKBB (6,477,810 SNPs passing quality checks). We summarize our genetic quality check steps. First, we excluded related individuals (up to 2nd-degree) from the complete UKBB sample using the KING software for family relationship inference[81]. We then removed duplicated variants from all 22 autosomal chromosomes. Individuals whose genetically identified sex did not match their self-acknowledged sex were removed. Other excluding criteria were: *i*) individuals with more than 3% of missing genotypes; *ii*) variants with minor allele frequency (MAF; dosage mode) of less than 1%; *iii*) variants with larger than 3% missing genotyping rate; *iv*) variants that failed the Hardy-Weinberg test at 1×10^{-10}. To further adjust for population stratification,[82] we derived the first 40 genetic principal components using the FlashPCA software[83]. Details of the genetic quality check protocol are described elsewhere[84,11,85,8,86].

(a) GWAS

Given the large sample sizes for both short vs. normal (16,872 short and 300,420 normal) and long vs. normal (25,049 long and 300,420 normal) sleep duration comparisons, we employed REGENIE[67] for GWAS, as it is well-suited for large-scale genetic analyses due to its computational efficiency and ability to control for population structure and relatedness, outperforming alternatives like PLINK and fastGWA in these settings. Our GWAS adjusted common variates, including age, disease status, age-squared, sex, interactions of age with sex, BMI, waist circumference, standing height, weight, systolic/diastolic blood pressure, and the first 40 genetic principal components. We applied a genome-wide significance threshold (5×10^{-8}) to annotate the significant independent genomic loci.

Annotation of genomic loci: For all GWASs, genomic loci were annotated using FUMA[87]. For genomic loci annotation, FUMA initially identified lead SNPs (correlation $r^2 \leq 0.1$, distance < 250 kilobases) and assigned them to non-overlapping genomic loci. The lead SNP with the lowest P-value (i.e., the top lead SNP) represented the genomic locus. Further details on the

definitions of top lead SNP, lead SNP, independent significant SNP, and candidate SNP can be found in **Supplementary Note 2**.

(b) MAGMA Tissue Expression Analysis
MAGMA gene-property analysis[32] was conducted using gene expression data from the GTEx (v8) to investigate tissue-specific associations with genetic variants. Unlike differential gene expression enrichment tests focusing solely on prioritized genes, MAGMA leverages the full distribution of SNP p-values across the genome, providing a more comprehensive assessment of how genetic signals relate to gene expression patterns in various tissues.

(d) Genetic correlation
We estimated the genetic correlation (g_c) using the LDSC[31] software between the two abnormal sleep duration patterns and 527 disease endpoints from the FinnGen and PGC datasets. We employed precomputed LD scores from the 1000 Genomes of European ancestry, maintaining default settings for other parameters in LDSC. It's worth noting that LDSC corrects for sample overlap, ensuring an unbiased genetic correlation estimate[88]. Statistical significance was determined using Bonferroni correction.

Method 8: Survival analyses for risk of disease endpoints and all-cause mortality
We evaluated the predictive value of abnormal sleep duration patterns, specifically short sleep (<6 hours) and long sleep (>8 hours), through two sets of analyses: *i*) survival analysis to assess the risk of time to incident single disease outcomes defined by ICD-10 codes, and *ii*) survival analysis to estimate the risk of all-cause mortality.

(a) Survival analysis for ICD-based single disease endpoint: we employed a Cox proportional hazard model while adjusting for covariates(i.e., age and sex) to test the associations of short/long sleep duration, compared to normal sleep duration ([6-8] hours), with the time to incident of ICD-based single disease entities. Notably, we excluded individuals with any prior disease diagnosis (except the disease of interest) to ensure the analysis was restricted to a disease-free population. The covariates, age, sex, body mass index, height, weight, waist circumference, and blood pressure, were included as additional right-side variables in the model. To train the model, the "time" variable was determined by calculating the difference between the date of death (Field ID: 40000) for cases (or the censoring date for non-cases) and the date attending the assessment center (Field ID: 53). Participants who were diagnosed for a specific disease of interest after enrolling in the study were classified as cases; non-cases were defined by participants without any disease diagnoses.

(b) Survival analysis for mortality risk: we employed a Cox proportional hazard model while adjusting for covariates(i.e., age and sex) to test the associations of short/long sleep duration patterns with all-cause mortality. The covariates, age, sex, body mass index, height, weight, waist circumference, and blood pressure, were included as additional right-side variables in the model. The hazard ratio (HR), $\exp(\beta_R)$, was calculated and reported as the effect size measure that indicates the influence of each biomarker on the risk of mortality. To train the model, the "time" variable was determined by calculating the difference between the date of death (Field ID: 40000) for cases (or the censoring date for non-cases) and the date attending the assessment

center (Field ID: 53). Participants who passed away after enrolling in the study were classified as cases.

Method 9: Structural equation modeling for mediation analysis
Using UKBB data, we used SEM to examine whether organ-specific MRIBAGs, measured at the second imaging visit (2014+), serve as mediators in the relationship between sleep duration, assessed at the baseline visit (2007-2010), and two distinct subtypes of late-life depression (LLD1 and LLD2), also evaluated at the second visit. Sleep duration was categorized into binary groups reflecting short (<6 hours) and long sleep (>8 hours) patterns, with respect to the normal sleep duration ([6-8] hours).

For each MRIBAG, we specified a mediation model (sleep duration → MRIBAG → LLD) that included: *i*) a direct path from sleep duration to LLD subtype (c2), and *ii*) an indirect path from sleep duration to MRIBAG (a1), and from MRIBAG to LLD subtype (c1), with the product term (a1×c1) representing the mediated (indirect) effect. Models were adjusted for relevant covariates, including age at assessment, sex, weight, standing height, waist circumference, BMI, diastolic blood pressure, and systolic blood pressure. To assess the robustness of causal directionality considering the time-ordering of events, we also tested reversed models (sleep duration → LLD1/2 → brain MRIBAG) to scrutinize potential inverse mediation. Significance was determined using a Bonferroni-corrected threshold ($P < 0.05/7$) to account for multiple comparisons across the 7 organ systems. All model estimates, including direct, indirect, total effects, and proportion mediated, are reported in the Supplementary Materials.

Data Availability

The GWAS summary statistics for the 23 multi-organ BAGs are publicly accessible via the MEDICINE portal (https://labs-laboratory.com/medicine/). The GWAS summary statistics for long and short sleep duration are publicly available via the Sleep Chart portal (https://labs-laboratory.com/sleepchart). All GWAS summary statistics are also available at Synapse (https://www.synapse.org/Synapse:syn64923248/wiki/630992[89] and https://www.synapse.org/Synapse:syn68602065/wiki/633329[90]). Our study used data generated by the Human Protein Atlas (https://www.proteinatlas.org) and MetaboAnalyst (https://www.metaboanalyst.ca/MetaboAnalyst/ModuleView.xhtml). GWAS summary data for the DEs were downloaded from the official websites of FinnGen (R9: https://www.finngen.fi/en/access_results) and PGC (https://pgc.unc.edu/for-researchers/download-results/). Individual data from UKBB can be requested with proper registration at https://www.ukbiobank.ac.uk/. The data used to replicate the main signal in UKBB comes from TriNetX (https://trinetx.com/), which requires a valid registration and request.

Code Availability

The software and resources used in this study are all publicly available:

- MLNI[91] (v0.1.2): https://github.com/anbai106/mlni, BAG generation;
- MGCV (v1.9.1) with R v4.2.2: https://cran.r-project.org/web/packages/mgcv/index.html, nonlinear GAM modeling
- GAMLSS (v5.4.22) with R v4.2.2: https://www.gamlss.com/; replicate the 9 sleep-BAG signals identified by the GAM modeling.
- Lifelines (v0.27.8): https://lifelines.readthedocs.io/en/latest/, survival analysis;
- Lavaan (v0.6.19): https://lavaan.ugent.be/, mediation analysis;
- String (v12.0): https://string-db.org/, protein set enrichment analyses and network analysis;
- MetaboAnalyst (v6.0): https://www.metaboanalyst.ca/, metabolite enrichment analysis and network analysis;
- REGENIE (v4.1): https://rgcgithub.github.io/regenie/, binary GWAS;
- LDSC (git version aa33296): https://github.com/bulik/ldsc, genetic correlation
- FUMA (v1.8.0): https://fuma.ctglab.nl/, Gene mapping, genomic locus annotation

Competing Interests

All authors state that we have no competing interests.

Authors' contributions

Dr. Wen has full access to all the study data and is responsible for its integrity and accuracy.
Study concept and design: W.J.
Drafting of the manuscript: W.J.
Critical revision of the manuscript for important intellectual content: All authors
Analysis: W.J. ran all main analyses. O.K.C. helped review the analysis. W.J. and S.Z. developed the Sleep Chart portal. A.F. ran analyses for TriNetX.

References

1. Ramar, K. *et al.* Sleep is essential to health: an American Academy of Sleep Medicine position statement. *Journal of Clinical Sleep Medicine* **17**, 2115–2119.

2. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. Hallmarks of aging: An expanding universe. *Cell* **186**, 243–278 (2023).

3. Diao, T. *et al.* Changes in Sleep Patterns, Genetic Susceptibility, and Incident Cardiovascular Disease in China. *JAMA Network Open* **7**, e247974 (2024).

4. Cappuccio, F. P., D'Elia, L., Strazzullo, P. & Miller, M. A. Sleep Duration and All-Cause Mortality: A Systematic Review and Meta-Analysis of Prospective Studies. *Sleep* **33**, 585–592 (2010).

5. Fan, M. *et al.* Sleep patterns, genetic susceptibility, and incident cardiovascular disease: a prospective study of 385□292 UK biobank participants. *European Heart Journal* **41**, 1182–1189 (2020).

6. Leng, Y., McEvoy, C. T., Allen, I. E. & Yaffe, K. Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment: A Systematic Review and Meta-analysis. *JAMA Neurology* **74**, 1237–1245 (2017).

7. Hamilton, O. S., Steptoe, A. & Ajnakina, O. Polygenic predisposition, sleep duration, and depression: evidence from a prospective population-based cohort. *Transl Psychiatry* **13**, 1–7 (2023).

8. Wen, J. *et al.* Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. *JAMA Psychiatry* (2022) doi:10.1001/jamapsychiatry.2022.0020.

9. Livingston, G. *et al.* Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet* **404**, 572–628 (2024).

10. The MULTI Consortium & Wen, J. Multi-organ MRI digitizes biological aging clocks across proteomics, metabolomics, and genetics. *Nature Medicine (under revision).*

11. Wen, J. *et al.* The genetic architecture of multimodal human brain age. *Nat Commun* **15**, 2604 (2024).

12. Wen, J. Refining the generation, interpretation, and application of multi-organ, multi-omics biological aging clocks. *Nature Aging* 2025.02.06.25321803 (2025) doi:10.1038/s43587-025-00928-9.

13. Anagnostakis, F. *et al.* Multi-organ metabolome biological age implicates cardiometabolic conditions and mortality risk. *Nat Commun* **16**, 4871 (2025).

14. Oh, H. S.-H. *et al.* Organ aging signatures in the plasma proteome track health and disease. *Nature* **624**, 164–172 (2023).

15. Tian, Y. E. *et al.* Heterogeneous aging across multiple organ systems and prediction of chronic disease and mortality. *Nat Med* 1–11 (2023) doi:10.1038/s41591-023-02296-6.

16. You, Y. *et al.* Inverted U-shaped relationship between sleep duration and phenotypic age in US adults: a population-based study. *Sci Rep* **14**, 6247 (2024).

17. Wang, X. *et al.* U-shaped association between sleep duration and biological aging: Evidence from the UK Biobank study. *Aging Cell* **23**, e14159 (2024).

18. Tao, M.-H., Drake, C. L. & Lin, C.-H. Association of sleep duration, chronotype, social jetlag, and sleep disturbance with phenotypic age acceleration: A cross-sectional analysis. *Sleep Health* **10**, 122–128 (2024).

19. Wang, M. *et al.* Association between sleep traits and biological aging risk: a Mendelian randomization study based on 157 227 cases and 179 332 controls. *Sleep* **47**, zsad299 (2024).

20. The MULTI Consortium *et al.* Brain-heart-eye axis revealed by multi-organ imaging genetics and proteomics. *Nature BME (in press)* 2025.01.04.25319995 (2025) doi:10.1101/2025.01.04.25319995.

21. Wen, J. Towards a multi-organ and multi-omics medical digital twin. *Nat. Biomed. Eng (in press)*.

22. The MULTI Consortium & Wen, J. Multi-organ AI Endophenotypes Chart the Heterogeneity of Pan-disease in the Brain, Eye, and Heart. *Nature Mental Health (under revision)*.

23. Boquet-Pujadas, A. *et al.* MUTATE: a human genetic atlas of multiorgan artificial intelligence endophenotypes using genome-wide association summary statistics. *Briefings in Bioinformatics* **26**, bbaf125 (2025).

24. Cespedes, E. M. *et al.* Comparison of Self-Reported Sleep Duration With Actigraphy: Results From the Hispanic Community Health Study/Study of Latinos Sueño Ancillary Study. *Am J Epidemiol* **183**, 561–573 (2016).

25. Matthews, K. A. *et al.* Similarities and Differences in Estimates of Sleep Duration by Polysomnography, Actigraphy, Diary, and Self-reported Habitual Sleep in a Community Sample. *Sleep Health* **4**, 96–103 (2018).

26. Rigby, R. A. & Stasinopoulos, D. M. Generalized Additive Models for Location, Scale and Shape. *Journal of the Royal Statistical Society Series C: Applied Statistics* **54**, 507–554 (2005).

27. Zhang, G.-Q. *et al.* The National Sleep Research Resource: towards a sleep data commons. *J Am Med Inform Assoc* **25**, 1351–1358 (2018).

28. Chen, X. *et al.* Racial/Ethnic Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep* **38**, 877–888 (2015).

29. Ou, C. *et al.* Healthy sleep durations appear to vary across cultures. *Proceedings of the National Academy of Sciences* **122**, e2419269122 (2025).

30. Hirshkowitz, M. *et al.* National Sleep Foundation's updated sleep duration recommendations: final report. *Sleep Health* **1**, 233–243 (2015).

31. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).

32. Leeuw, C. A. de, Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLOS Computational Biology* **11**, e1004219 (2015).

33. The GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580–585 (2013).

34. Chen, J., Peng, G. & Sun, B. Alzheimer's disease and sleep disorders: A bidirectional relationship. *Neuroscience* **557**, 12–23 (2024).

35. Sun, X. *et al.* Sleep disturbance and psychiatric disorders: a bidirectional Mendelian randomisation study. *Epidemiol Psychiatr Sci* **31**, e26 (2022).

36. Besedovsky, L., Lange, T. & Born, J. Sleep and immune function. *Pflugers Arch* **463**, 121–137 (2012).

37. Besedovsky, L., Lange, T. & Haack, M. The Sleep-Immune Crosstalk in Health and Disease. *Physiol Rev* **99**, 1325–1380 (2019).

38. Irwin, M. R. Sleep and inflammation: partners in sickness and in health. *Nat Rev Immunol* **19**, 702–715 (2019).

39. Sharma, S. & Kavuru, M. Sleep and Metabolism: An Overview. *Int J Endocrinol* **2010**, 270832 (2010).

40. Morselli, L. L., Guyon, A. & Spiegel, K. Sleep and metabolic function. *Pflugers Arch* **463**, 139–160 (2012).

41. Anghel, L. *et al.* Sleep Disorders Associated with Neurodegenerative Diseases. *Diagnostics (Basel)* **13**, 2898 (2023).

42. Kim, T. W., Jeong, J.-H. & Hong, S.-C. The Impact of Sleep and Circadian Disturbance on Hormones and Metabolism. *Int J Endocrinol* **2015**, 591729 (2015).

43. Briançon-Marjollet, A. *et al.* The impact of sleep disorders on glucose metabolism: endocrine and molecular mechanisms. *Diabetology & Metabolic Syndrome* **7**, 25 (2015).

44. Spira, A. P. *et al.* Sleep Duration and Subsequent Cortical Thinning in Cognitively Normal Older Adults. *Sleep* **39**, 1121–1128 (2016).

45. Lo, J. C., Loh, K. K., Zheng, H., Sim, S. K. Y. & Chee, M. W. L. Sleep Duration and Age-Related Changes in Brain Structure and Cognitive Performance. *Sleep* **37**, 1171–1178 (2014).

46. Tai, X. Y., Chen, C., Manohar, S. & Husain, M. Impact of sleep duration on executive function and brain structure. *Commun Biol* **5**, 1–10 (2022).

47. Mander, B. A., Winer, J. R. & Walker, M. P. Sleep and Human Aging. *Neuron* **94**, 19–36 (2017).

48. Mong, J. A. & Cusmano, D. M. Sex differences in sleep: impact of biological sex and sex steroids. *Philos Trans R Soc Lond B Biol Sci* **371**, 20150110 (2016).

49. Walton, J. C., Bumgarner, J. R. & Nelson, R. J. Sex Differences in Circadian Rhythms. *Cold Spring Harb Perspect Biol* **14**, a039107 (2022).

50. Kohanmoo, A., Kazemi, A., Zare, M. & Akhlaghi, M. Gender-specific link between sleep quality and body composition components: a cross-sectional study on the elderly. *Sci Rep* **14**, 8113 (2024).

51. Itani, O., Jike, M., Watanabe, N. & Kaneita, Y. Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. *Sleep Med* **32**, 246–256 (2017).

52. Patel, S. R. & Hu, F. B. Short sleep duration and weight gain: a systematic review. *Obesity (Silver Spring)* **16**, 643–653 (2008).

53. Irwin, M. R. & Opp, M. R. Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity. *Neuropsychopharmacol* **42**, 129–155 (2017).

54. Marjot, T., Ray, D. W., Williams, F. R., Tomlinson, J. W. & Armstrong, M. J. Sleep and liver disease: a bidirectional relationship. *Lancet Gastroenterol Hepatol* **6**, 850–863 (2021).

55. Tononi, G. & Cirelli, C. Sleep and the Price of Plasticity: From Synaptic and Cellular Homeostasis to Memory Consolidation and Integration. *Neuron* **81**, 12–34 (2014).

56. Xie, L. *et al.* Sleep Drives Metabolite Clearance from the Adult Brain. *Science* **342**, 10.1126/science.1241224 (2013).

57. Frank, M. G. & Cantera, R. Sleep, clocks, and synaptic plasticity. *Trends Neurosci* **37**, 491–501 (2014).

58. Baril, A.-A. *et al.* Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype. *Alzheimers Dement* **18**, 408–421 (2022).

59. Tian, Y. E., Cole, J. H., Bullmore, E. T. & Zalesky, A. Brain, lifestyle and environmental pathways linking physical and mental health. *Nat. Mental Health* **2**, 1250–1261 (2024).

60. Dew, M. A. *et al.* Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. *Psychosom Med* **65**, 63–73 (2003).

61. Bliwise, D. L. Sleep in normal aging and dementia. *Sleep* **16**, 40–81 (1993).

62. Penninx, B. W., Milaneschi, Y., Lamers, F. & Vogelzangs, N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. *BMC Medicine* **11**, 129 (2013).

63. Milaneschi, Y., Lamers, F., Berk, M. & Penninx, B. W. J. H. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. *Biol Psychiatry* **88**, 369–380 (2020).

64. Austin-Zimmerman, I. *et al.* Genome-wide association studies and cross-population meta-analyses investigating short and long sleep duration. *Nat Commun* **14**, 6059 (2023).

65. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

66. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated population. *Nature* **613**, 508–518 (2023).

67. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* **53**, 1097–1103 (2021).

68. O'Donovan, M. C. What have we learned from the Psychiatric Genomics Consortium. *World Psychiatry* **14**, 291–293 (2015).

69. Palchuk, M. B. *et al.* A global federated real-world data and analytics platform for research. *JAMIA Open* **6**, ooad035 (2023).

70. Mojtahed, A. *et al.* Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. *Abdom Radiol* **44**, 72–84 (2019).

71. Whitcher, B. *et al.* Precision MRI phenotyping enables detection of small changes in body composition for longitudinal cohorts. *Sci Rep* **12**, 3748 (2022).

72. Parisinos, C. A. *et al.* Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. *J Hepatol* **73**, 241–251 (2020).

73. Karlsson, A. *et al.* Automatic and quantitative assessment of regional muscle volume by multi-atlas segmentation using whole-body water-fat MRI. *J Magn Reson Imaging* **41**, 1558–1569 (2015).

74. Borga, M. *et al.* Validation of a fast method for quantification of intra-abdominal and subcutaneous adipose tissue for large-scale human studies. *NMR Biomed* **28**, 1747–1753 (2015).

75. Liu, Y. *et al.* Genetic architecture of 11 organ traits derived from abdominal MRI using deep learning. *eLife* **10**, e65554 (2021).

76. Wen, J. *et al.* Convolutional neural networks for classification of Alzheimer's disease: Overview and reproducible evaluation. *Medical Image Analysis* **63**, 101694 (2020).

77. Li, W. UK Biobank pharma proteomics resource. *Nat Genet* **55**, 1781–1781 (2023).

78. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank. *Nature* **622**, 329–338 (2023).

79. Würtz, P. *et al.* Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. *American Journal of Epidemiology* **186**, 1084–1096 (2017).

80. Ritchie, S. C. *et al.* Quality control and removal of technical variation of NMR metabolic biomarker data in ~120,000 UK Biobank participants. *Sci Data* **10**, 64 (2023).

81. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**, 2867–2873 (2010).

82. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population stratification in genome-wide association studies. *Nat Rev Genet* **11**, 459–463 (2010).

83. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).

84. Wen, J. *et al.* Genomic loci influence patterns of structural covariance in the human brain. *Proceedings of the National Academy of Sciences* **120**, e2300842120 (2023).

85. Wen, J. *et al.* The genetic architecture of biological age in nine human organ systems. *Nat Aging* 1–18 (2024) doi:10.1038/s43587-024-00662-8.

86. Wen, J. *et al.* Genetic and clinical correlates of two neuroanatomical AI dimensions in the Alzheimer's disease continuum. *Transl Psychiatry* **14**, 1–14 (2024).

87. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).

88. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, 1236–1241 (2015).

89. Wen, J. MEDICINE: AI-derived GWAS summary statistics sharing portal. (2025) doi:10.7303/SYN64923248.

90. Wen, J. SleepChart: digitize sleep duration and biological aging clocks across organs and omics. (2025) doi:doi.org/10.7303/syn68602065.

91. Wen, J. MLNI (Version 0.1.4) [Computer software]. (2025) doi:https://github.com/anbai106/mlni.

92. Yeung, C.-Y. C. *et al.* Circadian regulation of protein cargo in extracellular vesicles. *Science Advances* **8**, eabc9061 (2022).

93. Scharf, M. T., Naidoo, N., Zimmerman, J. E. & Pack, A. I. The energy hypothesis of sleep revisited. *Prog Neurobiol* **86**, 264–280 (2008).

Acknowledgments

This research is supported through funding from the NIH-supported MULTI Consortium (W.J.; grant number: RF1AG092412). The MULTI consortium (J.W.; UK Biobank Application Number: 647044) aims to integrate multi-organ imaging and multi-omics data to advance our understanding of human aging and disease mechanisms. This study used the UK Biobank resource under Application Numbers 647044 (W.J.) and 35148 (D.C.; NIA grant number: RF1 AG054409). D.R.M., W.A.K., S.M.E., R.M.S., and F.L. are supported by the Intramural Research Program of the NIH, NIA. We want to express our sincere gratitude to the UK Biobank team for their invaluable contribution to advancing clinical research in our field (https://www.ukbiobank.ac.uk/). We want to acknowledge the participants and investigators of the FinnGen study and the PGC consortium, and we thank FinnGen (https://www.finngen.fi/en) and PGC (https://pgc.unc.edu/) for their generosity in sharing the GWAS summary statistics with the scientific community.

Extended figures

Extended Data Figure 1: **Sleep Chart delineates U-shaped associations between sleep duration and 720 organ-specific imaging-derived phenotypes**

a) Sleep duration was associated with 720 organ-specific imaging-derived phenotypes (IDP; x-axis) using the GAM model. Non-gray colored IDPs indicate significant associations after Bonferroni correction for multiple comparisons across all available IDPs (P<0.05/720). The y-axis shows the effective degrees of freedom (EDF), quantifying the degree of nonlinearity for the U-shaped patterns, with representative proteins annotated for each organ. **b**) The EDF brain map displays the EDF values for significant signals associated with brain IDPs derived from T1-weighted MRI. **c**) The EDF brain map displays the EDF values for significant signals associated with brain IDPs derived from fractional anisotropy (FA) using diffusion MRI. **d-j**) Representative IDPs from various organ systems and tissues illustrate U-shaped associations with sleep duration.

Extended Data Figure 2: **Sleep Chart delineates U-shaped associations between sleep duration and 342 organ-enriched proteins**

a) Sleep duration was associated with 342 organ-enriched plasma proteins (x-axis) using the GAM model. These organ/tissue-enriched proteins were defined in our previous study[12] via

resources from the Human Protein Atlas (https://www.proteinatlas.org/) project. Non-gray colored proteins indicate proteins with significant associations after Bonferroni correction for multiple comparisons across all available proteins (P<0.05/2923 for all available proteins). The y-axis shows the effective degrees of freedom (EDF), quantifying the degree of nonlinearity (e.g., U-shaped associations), with representative proteins annotated for each organ. **b**) Representative U-shaped relationship between the FGFR2 protein and sleep duration. **c-d**) Protein-protein interaction (PPI) network was conducted using STRING v12.0 (https://string-db.org/) to examine the functional relationships among 14 immune-enriched and 29 hepatic-enriched proteins. STRING integrates evidence from experimental data, computational predictions, and literature text mining, enabling the PPI network to reveal how these proteins may functionally interact within and across biological pathways, potentially offering insights into shared mechanisms and tissue-specific processes. **e**) We performed protein set enrichment analysis (PSEA) using STRING for organs with more than 9 significant proteins (i.e., the hepatic and immune) to identify over-represented Gene Ontology (GO) terms across biological processes, molecular functions, and cellular components. Icon sizes in the visualization reflect the statistical significance, represented by the -$\log_{10}$(FDR-corrected P). The strength measurement (x-axis) is a log-scale enrichment ratio that shows the magnitude of enrichment. We group distinct GO terms along the y-axis by associating each biological pathway with potential sleep-related hypotheses informed by prior literature, such as the immune activation and inflammation hypothesis[37] or the Extracellular signaling and vesicle transport hypothesis[92].

Extended Data Figure 3: **Sleep Chart delineates U-shaped associations between sleep duration and 107 organ-associated metabolites**

a) Sleep duration was associated with 107 organ-associated plasma metabolites (x-axis) using the GAM model. These organ-associated metabolites were defined in our previous study[13]. Non-gray colored points indicate significant associations after Bonferroni correction for multiple comparisons across all available metabolites ($p < 0.05/327$ for all available metabolites). The y-axis displays the effective degrees of freedom (EDF), quantifying the extent of nonlinearity for the U-shaped associations. We annotated representative proteins for each organ system. **b-e**) Representative U-shaped relationship between 4 metabolites or lipid subclasses and sleep

duration. **f)** Metabolite set enrichment analysis (MSEA) was performed using the Over Representation Analysis (ORA) module in MetaboAnalyst (https://www.metaboanalyst.ca/), which identifies biologically meaningful patterns by assessing whether known metabolite sets (e.g., significant metabolites related to sleep duration) are overrepresented among the list of input metabolites. The analysis uses a hypergeometric test to calculate statistical significance, with multiple testing correction applied using the FDR method. Only metabolite sets with FDR < 0.05 were considered significantly enriched. Only small-molecule metabolites, excluding lipid subclasses, that could be mapped in MetaboAnalyst were included. As the background reference, we used 3,694 metabolite and lipid pathways curated in RaMP-DB (integrating KEGG via HMDB, Reactome, and WikiPathways). We organize distinct metabolite sets along the y-axis by linking them to potential sleep-related hypotheses grounded in prior literature, including the sleep-liver axis, which is closely tied to the energy hypothesis[93] of sleep.

Extended Data Figure 4: **Associations between sleep duration and the polygenic risk score (PRS) of the 23 multi-organ, multi-omics BAGs**

Unlike the BAGs, sleep duration (x-axis) did not exhibit a U-shaped relationship with the polygenic risk scores (PRS) of the 23 BAGs derived from common genetic variants (y-axis).

Extended Data Figure 5: **Insomnia and hypersomnia are associated with the time to incident of the 110 disease endpoints and mortality in the TriNetX database**

Using insomnia and hypersomnia as proxies for short and long sleep duration, respectively, we replicated the significant associations shown in Fig. 4 within the UK Biobank cohort. Disease endpoints that remained significant after Bonferroni correction (0.05/111, accounting for 110

comorbidity-free disease endpoints and all-cause mortality) are indicated by colored shapes, while non-significant associations are shown in gray. One additional disease category was also tested for all types of dementia.

The MULTI Study

Junhao Wen[1,4,19,20,21,22,23,&], Cliodhna Kate O'Toole[1], Christos Davatzikos[18], Ye Ella Tian[6], Andrew Zalesky[6], Luigi Ferrucci[17], Wenjia Bai[8], Michael S. Rafii[10], Paul Aisen[10], Keenan A. Walker[7]

[1]Laboratory of AI and Biomedical Science (LABS), Columbia University, New York, NY, USA
[4]Department of Radiology, Columbia University, New York, NY, USA
[6]Melbourne Neuropsychiatry Centre, Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
[7]Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
[8]Department of Brain Sciences and Department of Computing, Imperial College London, London, UK
[10]Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of Southern California, San Diego, CA 92121, USA
[17]National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
[18]Artificial Intelligence in Biomedical Imaging Laboratory (AIBIL), Center for AI and Data Science for Integrated Diagnostics (AI²D), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
[19]Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID), Department of Radiology, Columbia University, New York, NY, USA
[20]Department of Biomedical Engineering, Columbia University, New York, NY, USA
[21]Zuckerman Institute, Columbia University, New York, NY, USA
[22]New York Genome Center (NYGC), New York, NY, USA
[23]Data Science Institute (DSI), Columbia University, New York, NY, USA
&Study representative: Dr. Junhao Wen